Sialorrhea Treatment Market Growth Report | Size, Share & Forecast Analysis 2030

Sialorrhea Treatment Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Medical Therapy (Pharmacologic Therapy and Radiotherapy) and End User (Hospitals, Specialty Clinics, Homecare Settings, and Others)

  • Report Code : TIPRE00033418
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

[Research Report] The sialorrhea treatment market was valued at US$ 695.06 million in 2022 and is expected to reach US$ 1,042.37 million by 2030; it is estimated to record a CAGR of 5.2% from 2022 to 2030.

Market Insights and Analyst View:

The sialorrhea refers to excessive saliva production. When individuals have extensive posterior saliva leakage down their tracheas instead of being routinely swallowed, it is known as posterior sialorrhea. Patients affected by anterior sialorrhea experience excessive anterior or forward salivation, also known as drooling, onto their faces and clothing, which makes it difficult for them to maintain hygiene, take care of their skin, and interact with others. Aspiration, a long-term lung irritation caused by this, can occasionally lead to pneumonia.

Growth Drivers and Challenges:

Patients suffering from neurological illnesses have a higher chance of developing chronic sialorrhea. Sialorrhea is typically treated with symptoms resulting from long-term neurological disorders, which adds to the overall load on patients. Physical and psychological burdens of patients can negatively affect their quality of life. People who suffer from neurological conditions such as cerebral palsy, Parkinson's disease, stroke, or ALS are primarily affected by chronic sialorrhea. These disorders impair the muscular coordination necessary for swallowing and saliva management. Damage or degeneration of the nerves is a result of ALS or Parkinson's disease. The brain, salivary glands, and swallowing muscles are main signal transducers for these nerves. Signal disruption, poor swallowing, and salivary gland coordination result from the damage. According to a article published by the Journal of Clinical Neuroscience, in 2019, ~40% of children affected by cerebral palsy and 80% of adults suffering from Parkinson’s disease were having sialorrhea. The abovementioned factors drive the sialorrhea treatments market growth.

Adverse effects of pharmacologic therapy are irritation, restlessness, sedation, and delirium from the central effects of the drugs. Inhibition of gastrointestinal (GI) motility has resulted in worsening constipation in a population already plagued with such difficulties. Photophobia, urinary retention, and facial flushing are other side effects of the medications.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Sialorrhea Treatment Market: Strategic Insights

sialorrhea-treatment-market
Market Size Value inUS$ 695.06 million in 2022
Market Size Value byUS$ 1,042.37 million by 2030
Growth rateCAGR of 5.2% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The sialorrhea treatment market is bifurcated on the basis of medical therapy and end user. By medical treatment, the market is segmented into pharmacologic therapy, radiotherapy, and others. The sialorrhea treatment market, by end user, is segmented into hospitals, specialty clinics, homecare settings, and others. The sialorrhea treatment market, based on geography, is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America)

Segmental Analysis:

Based on medical therapy, the sialorrhea treatment market is segmented into pharmacologic therapy, radiotherapy, and others. In 2022, the pharmacologic therapy segment held the largest market share. Also, the segment is expected to record the highest CAGR during 2022–2030. Vaccines provide active acquired immunity against particular infectious diseases. In multiple independent clinical trials, pharmacological treatments such as benztropine, glycopyrrolate, scopolamine, and botulinum toxins have been demonstrated to be effective in managing sialorrhea. Medications are delivered orally or parenterally. Botulinum toxin is injected into the salivary gland guided by anatomical external palpation or ultrasonography.

The sialorrhea treatment market, by end user, is segmented into hospitals, specialty clinics, homecare settings, and others. The hospitals segment held the largest market share in 2022 and is anticipated to record the highest CAGR during 2022–2030. The treatment for sialorrhea is done in hospitals through appropriate treatment and motor therapy, with the help of highly experienced interdisciplinary medical specialists, including physiotherapists and neurology specialists.

Regional Analysis:

Based on region, the sialorrhea treatment market is categorized into five key regions—North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. The market in North America has been analyzed with a prime focus on three major countries—the US, Canada, and Mexico. Asia Pacific is expected to record the highest CAGR in the sialorrhea treatment market during 2022–2030. Growing government initiatives to increase awareness regarding this condition, increasing research and development activities in the region, growing market players' shifts toward providing better treatment options are among the prominent factors propelling the sialorrhea treatment market growth.

Sialorrhea Treatment Market Opportunity:

Improvised Curative Gene Therapy for Sialorrhea Treatment to Offer Lucrative Opportunities for Sialorrhea Treatment Market During Forecast Period

According to NIH, an experimental trial showed that gene therapy can be executed safely in the human salivary gland. The gene helps salivary gland cells secrete saliva into the mouth. Ad5-mediated transfer of the N-myc downstream-regulated gene 2 (NDRG2) to correct the salivary hypofunction. Also, use of NDRG2 gene transfer may be useful clinically for postmenopausal women who suffer from salivary hypofunction and do not want to risk the side effects of estrogen supplementation therapy. Therefore, the abovementioned factors are expected to provide opportunities for the sialorrhea treatment market in the coming years.  

Sialorrhea Treatment Market Report Scope

Competitive Landscape and Key Companies:

Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK Plc., Bayer AG, and Sun Pharmaceutical Industries Ltd. are among the prominent players operating in the global sialorrhea treatment market. These companies focus on the development of new technologies, advancements in existing products, and expansion of geographic footprint to meet the growing consumer demand worldwide and expand their product range in specialty portfolios. Companies operating in the global sialorrhea treatment market are implementing various inorganic and organic strategies. A few of them are mentioned below:

  • In August 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, was granted the use of XEOMIN for the symptomatic treatment of chronic sialorrhea in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg due to neurodevelopmental disorders/neurological on EU level. The US Food and Drug Administration approved it in December 2020, and the Russian Federal Service for Surveillance in Healthcare August 2021.
  • In February 2023, Proveca Pharma Ltd, a pharmaceutical company that specializes in medicines for children, provided Sialanar (glycopyrronium bromide) to children suffering from severe sialorrhea due to chronic neurological disorders in France.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Medical Therapy, and End User

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is meant by the sialorrhea treatment market?

The term "hypersalivation," or "sialorrhea," refers to excessive saliva production. When individuals have extensive posterior saliva leakage down their tracheas instead of being routinely swallowed, it is known as posterior sialorrhea. Patients with anterior sialorrhea experience excessive anterior or forward salivation, also known as drooling, onto their faces and clothing, which makes it difficult for them to maintain hygiene, take care of their skin, and interact with others. Aspiration, a long-term lung irritation caused by this, can occasionally lead to pneumonia.

Which medical therapy segment led the sialorrhea treatment market?

Based on medical therapy, the pharmacologic therapy segment took the forefront leaders in the worldwide market by accounting largest share in 2022 and is expected to continue to do so till the forecast period.

What are the driving factors for the sialorrhea treatment market across the globe?

Increasing prevalence of neurodegenerative disorders and various treatment options available for sialorrhea treatment are the most significant factors responsible for the overall market growth.

Who are the key players in the sialorrhea treatment market?

Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK Plc., Bayer AG, and Sun Pharmaceutical Industries Ltd among others are among the leading companies operating in the sialorrhea treatment market.

What is the regional market scenario of the sialorrhea treatment market?

Sialorrhea treatment market is segmented by regions comprising of North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.

Which end user segment held the largest market share in the sialorrhea treatment market?

The hospitals segment dominated the sialorrhea treatment market and accounted for the largest market share in 2022.

1. Introduction

1.1 Scope of the Study

1.2 Market Definition, Assumptions and Limitations

1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness Analysis

3. Research Methodology

4. Sialorrhea Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Sialorrhea Market - Key Market Dynamics

5.1 Key Market Drivers

5.2 Key Market Restraints

5.3 Key Market Opportunities

5.4 Future Trends

5.5 Impact Analysis of Drivers and Restraints

6. Sialorrhea Market - Global Market Analysis

6.1 Sialorrhea - Global Market Overview

6.2 Sialorrhea - Global Market and Forecast to 2030

7. Sialorrhea Market – Revenue Analysis (USD Million) – By Medical Therapy, 2020-2030

7.1 Overview

7.2 Pharmacologic Therapy

7.2.1 Anticholinergic

7.2.2 Botulinum Toxins

7.3 Radiotherapy

7.4 Others

8. Sialorrhea Market – Revenue Analysis (USD Million) – By End User, 2020-2030

8.1 Overview

8.2 Hospitals

8.3 Specialty Clinics

8.4 Homecare Settings

8.5 Others

9. Sialorrhea Market - Revenue Analysis (USD Million), 2020-2030 – Geographical Analysis

9.1 North America

9.1.1 North America Sialorrhea Market Overview

9.1.2 North America Sialorrhea Market Revenue and Forecasts to 2030

9.1.3 North America Sialorrhea Market Revenue and Forecasts and Analysis - By Medical Therapy

9.1.4 North America Sialorrhea Market Revenue and Forecasts and Analysis - By End User

9.1.5 North America Sialorrhea Market Revenue and Forecasts and Analysis - By Countries

9.1.5.1 United States Sialorrhea Market

9.1.5.1.1 United States Sialorrhea Market, by Medical Therapy

9.1.5.1.2 United States Sialorrhea Market, by End User

9.1.5.2 Canada Sialorrhea Market

9.1.5.2.1 Canada Sialorrhea Market, by Medical Therapy

9.1.5.2.2 Canada Sialorrhea Market, by End User

9.1.5.3 Mexico Sialorrhea Market

9.1.5.3.1 Mexico Sialorrhea Market, by Medical Therapy

9.1.5.3.2 Mexico Sialorrhea Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

9.2 Europe

9.2.1 Germany

9.2.2 France

9.2.3 Italy

9.2.4 Spain

9.2.5 United Kingdom

9.2.6 Rest of Europe

9.3 Asia-Pacific

9.3.1 Australia

9.3.2 China

9.3.3 India

9.3.4 Japan

9.3.5 South Korea

9.3.6 Rest of Asia-Pacific

9.4 Middle East and Africa

9.4.1 South Africa

9.4.2 Saudi Arabia

9.4.3 U.A.E

9.4.4 Rest of Middle East and Africa

9.5 South and Central America

9.5.1 Brazil

9.5.2 Argentina

9.5.3 Rest of South and Central America

10. Industry Landscape

10.1 Mergers and Acquisitions

10.2 Agreements, Collaborations, Joint Ventures

10.3 New Product Launches

10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players

11.2 Company Positioning and Concentration

12. Sialorrhea Market - Key Company Profiles

12.1 Supernus Pharmaceuticals, Inc.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

Note - Similar information would be provided for below list of companies

12.2 Proveca Ltd

12.3 Merz Pharmaceuticals, LLC.

12.4 Allergan

12.5 GlaxoSmithKline

12.6 Shionogi Inc.

12.7 BAYER INC

12.8 Novartis Pharmaceuticals Corporation

12.9 Nobelpharma Co., Ltd.

12.10 Bristol-Myers Squibb Company

13. Appendix

13.1 Glossary

13.2 About The Insight Partners

13.3 Market Intelligence Cloud

The List of Companies - Sialorrhea Treatment Market

  1. Pfizer Inc
  2. F. Hoffmann-La Roche Ltd
  3. Mylan N.V.
  4. Fresenius Kabi AG
  5. Hikma Pharmaceuticals PLC
  6. Novartis AG
  7. Teva Pharmaceutical Industries Ltd.
  8. Bristol Myers Squibb Company
  9. GSK Plc.
  10. Bayer AG
  11. Sun Pharmaceutical Industries Ltd

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Sialorrhea Treatment Market